These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32156613)

  • 1. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
    Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
    Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the presence of doubly phosphorylated α-synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases.
    Fayyad M; Erskine D; Majbour NK; Vaikath NN; Ghanem SS; Sudhakaran IP; Abdesselem H; Lamprokostopoulou A; Vekrellis K; Morris CM; Attems J; El-Agnaf OMA
    Brain Pathol; 2020 Jul; 30(4):831-843. PubMed ID: 32324926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
    Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
    PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
    Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
    Vaikath NN; Erskine D; Morris CM; Majbour NK; Vekrellis K; Li JY; El-Agnaf OMA
    Neuropathol Appl Neurobiol; 2019 Oct; 45(6):597-608. PubMed ID: 30422353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
    Oueslati A
    J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological roles of α-synuclein serine-129 phosphorylation - not an oxymoron.
    Ramalingam N; Haass C; Dettmer U
    Trends Neurosci; 2024 Jul; 47(7):480-490. PubMed ID: 38862330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific Detection of Physiological S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay.
    Arlinghaus R; Iba M; Masliah E; Cookson MR; Landeck N
    J Parkinsons Dis; 2023; 13(2):255-270. PubMed ID: 36847016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity and specificity of phospho-Ser129 α-synuclein monoclonal antibodies.
    Delic V; Chandra S; Abdelmotilib H; Maltbie T; Wang S; Kem D; Scott HJ; Underwood RN; Liu Z; Volpicelli-Daley LA; West AB
    J Comp Neurol; 2018 Aug; 526(12):1978-1990. PubMed ID: 29888794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral Deficits and Brain α-Synuclein and Phosphorylated Serine-129 α-Synuclein in Male and Female Mice Overexpressing Human α-Synuclein.
    Gabrielyan L; Liang H; Minalyan A; Hatami A; John V; Wang L
    J Alzheimers Dis; 2021; 79(2):875-893. PubMed ID: 33361597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic reversibility of α-synuclein serine-129 phosphorylation is impaired in synucleinopathy models.
    Ramalingam N; Brontesi L; Jin SX; Selkoe DJ; Dettmer U
    EMBO Rep; 2023 Dec; 24(12):e57145. PubMed ID: 37870370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Novel Electrochemiluminescence ELISA for Quantification of α-Synuclein Phosphorylated at Ser
    Dutta S; Hornung S; Taha HB; Biggs K; Siddique I; Chamoun LM; Shahpasand-Kroner H; Lantz C; Herrera-Vaquero M; Stefanova N; Loo JA; Bitan G
    ACS Chem Neurosci; 2023 Apr; 14(7):1238-1248. PubMed ID: 36920792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice.
    Butler YR; Liu Y; Kumbhar R; Zhao P; Gadhave K; Wang N; Li Y; Mao X; Wang W
    Nat Commun; 2022 Jul; 13(1):4060. PubMed ID: 35853942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.
    Chatterjee D; Sanchez DS; Quansah E; Rey NL; George S; Becker K; Madaj Z; Steiner JA; Ma J; Escobar Galvis ML; Kordower JH; Brundin P
    J Parkinsons Dis; 2019; 9(2):315-326. PubMed ID: 30932894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.
    Walker DG; Lue LF; Adler CH; Shill HA; Caviness JN; Sabbagh MN; Akiyama H; Serrano GE; Sue LI; Beach TG;
    Exp Neurol; 2013 Feb; 240():190-204. PubMed ID: 23201181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against alpha-synuclein: tools and therapies.
    Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
    J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease.
    Oueslati A; Paleologou KE; Schneider BL; Aebischer P; Lashuel HA
    J Neurosci; 2012 Feb; 32(5):1536-44. PubMed ID: 22302797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.